Clinical trials: Cancer Vaccine
Cancer of the Head and Neck
Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without GITR Agonist, With Anti-PD-1 Immunotherapy in HNSCC
This is a phase Ib study with a safety lead-in (n = 6 per arm) evaluating combinatorial DPV-001 + sequenced PD-1 blockade, with or without GITR agonist, in recurrent or metastatic HNSCC.
- Trial name
- NCT04470024
- Testing
- INCAGN01876, INCMGA00012, DPV-001
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Providence Health & Services
Cholangiocarcinoma
Trial of Therapeutic Vaccine in Patients With Cholangiocarcinoma
Cholangiocarcinoma (CCA) is a malignant neoplasm originating from the epithelial cells lining the intra- or extrahepatic biliary ducts. It is the second-most common liver cancer, after hepatocellular carcinoma (HCC).
- Trial name
- cholangio (NCT03042182)
- Testing
- Oral therapeutic vaccine V3-X to treat cholangiocarcinoma
- Where
- 2 sites in Mongolia
- Volunteers
- 20 people
- Sponsor
- Immunitor LLC
Prostate Cancer
Vaccine Therapy With or Without Docetaxel in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00045227
- Testing
- recombinant fowlpox-prostate specific antigen vaccine, recombinant vaccinia prostate-specific antigen vaccine, recombinant vaccinia-B7.1 vaccine
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Melanoma
Melanoma Vaccine With Peptides and Leuprolide
The goal of this clinical research study is to learn if the drug leuprolide will increase the level of immune cells in your body.
- Trial name
- NCT00254397
- Testing
- Leuprolide, GP100: 209-217(210M) Peptide, MAGE-3 Peptide
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- M.D. Anderson Cancer Center
Warts, Genital, Neoplasms, Anal
Efficacy, Immunogenicity, and Safety Study of V503 (9-valent Human Papillomavirus [9vHPV] Vaccine) in Japanese Males (V503-064)
The purposes of this phase 3, double-blind, placebo-controlled clinical study are to evaluate the efficacy of V503 in preventing human papillomavirus (HPV)-related anogenital persistent infection, and to evaluate the…
- Trial name
- NCT04635423
- Testing
- V503
- Where
- 22 sites in Japan
- Volunteers
- 1,059 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Melanoma (Skin)
Vaccine Therapy and Resiquimod in Treating Patients With Stage II, Stage III, or Stage IV Melanoma That Has Been Completely Removed by Surgery
RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Giving vaccine therapy together with resiquimod may make a stronger immune response and prevent or delay the…
- Trial name
- NCT00470379
- Testing
- resiquimod
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mayo Clinic
Breast Cancer
Pilot Study of a Breast Cancer Vaccine Plus Poly-ICLC for Breast Cancer
Despite advances in surgical, radiation and medical therapies of early stage breast cancer, some patients will experience disease recurrence.
- Trial name
- Breast 41 (NCT01532960)
- Testing
- poly-ICLC, 9 Peptides from Her-2/neu, CEA, & CTA, Peptide-tet
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Craig L Slingluff, Jr
Colorectal Cancer, Small Bowel Adenocarcinoma
GUCY2C Prime-Boost Vaccination for Advanced Colorectal and Small Bowel Adenocarcinomas
This is an open-label, non-randomized, single-center, dose-escalation Phase 1 trial using a heterologous prime-boost strategy of vaccination with Ad5.F35-hGUCY2C-PADRE and recombinant Listeria monocytogenes (Lm-GUCY2C) vaccines…
- Trial name
- NCT07417488
- Testing
- Ad5.F35-hGUCY2C-PADRE vaccine, Lm-GUCY2C vaccine, CT Scan
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Thomas Jefferson University
Recurrent Human Papillomavirus Type 16 Associated Cancer
TA-CIN Vaccine With Anti-PD-1 Therapy in Recurrent HPV16-associated Cancers
The primary to assess the safety and tolerability of TA-CIN and anti-PD-1 therapy in patients with recurrent HPV16-associated cancers and to assess the feasibility of IT injection of TA-CIN in patients with recurrent…
- Trial name
- NCT05132803
- Testing
- HPV 16 TA-CIN
- Where
- 2 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Melanoma
Safety Study of a Liposomal Vaccine to Treat Malignant Melanoma
The purpose of this study is to determine whether Lipovaxin-MM, a new anti-cancer vaccine, is safe and effective in improving the body's ability to destroy cancer cells in patients with metastatic melanoma.
- Trial name
- NCT01052142
- Testing
- Lipovaxin-MM
- Where
- Australia
- Volunteers
- 12 people
- Sponsor
- Lipotek Pty Ltd
Cutaneous Melanoma, Synovial Sarcoma
ACTengine® IMA203 Combined With mRNA-4203
This purpose of this clinical trial is to evaluate the safety, tolerability and anti-tumor activity of IMA203 in combination with different doses of mRNA-4203.
- Trial name
- NCT06946225
- Testing
- IMA203, mRNA-4203
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- Immatics US, Inc.
Glioblastoma
Personalized Cellular Vaccine for Glioblastoma (PERCELLVAC)
Dendritic cell-based cellular vaccine for tumor therapy has shown efficacy. This study is designed to perform a personalized clinical trial by first analyzing the expression of tumor associated antigens in patients with newly…
- Trial name
- PERCELLVAC (NCT02709616)
- Testing
- Personalized cellular vaccine
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Guangdong 999 Brain Hospital
Cancer Patients, Vaccine-Preventable Diseases
Vaccine Hesitancy in Patients with Solid Tumors: a Cross-sectional Single-center Survey
Cancer patients have a well-known and higher risk of vaccine-preventable disease (VPD) than the general population. VPD can cause serious complications due to compromised immune system, malnutrition and the same oncology…
- Trial name
- VE (NCT06872814)
- Where
- Italy
- Volunteers
- 309 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Human Papillomavirus Infection, HPV
Human Papillomavirus in Young People Epidemiological Research 3
Anal cancer is overrepresented among gay, bisexual and other men who have sex with men (MSM), particularly those living with HIV.
- Conditions
- Human Papillomavirus Infection, HPV, HPV Infection, Anal Cancer
- Trial name
- HYPER3 (NCT05587725)
- Where
- Australia
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Monash University
HPV Infections, Cervical Cancer Stage IIa
Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years
This phase 3 study will evaluate the immunogenicity and safety of Quadrivalent HPV recombinant vaccine in Chinese females aged 9 to 26 years
- Conditions
- HPV Infections, Cervical Cancer Stage IIa, Vaginal Cancer, Genital Wart
- Trial name
- NCT05027776
- Testing
- 2-doses Group among 9-14 years, 3-doses Group among 9-19 years, 3-doses Group among 20-26 years
- Where
- China
- Volunteers
- 1,348 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Lung Cancer
Vaccine Therapy in Treating Patients With Non-Small Cell Lung Cancer
RATIONALE: Vaccines made from a person's tumor cells and white blood cells may make the body build an immune response to kill tumor cells.
- Trial name
- NCT00023985
- Testing
- autologous tumor cell vaccine, therapeutic autologous dendritic cells, conventional surgery
- Where
- United States
- Sponsor
- Roswell Park Cancer Institute
Cervical Cancer
Acceptability and Feasibility of Human Papilloma Virus Vaccine
The overall program goal is to determine the Acceptability and Feasibility of introducing a population based Human Papilloma Virus (HPV) Vaccination programme and understanding the key individual and community factors that would…
- Trial name
- NCT01209338
- Testing
- Health education
- Where
- India
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Tata Memorial Hospital
Mesothelioma, Malignant, PD-L1 Negative
Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients with PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies
Pembrolizumab plus autologous dendritic cell vaccine in patients with PD-L1 negative advanced mesothelioma who have failed prior therapies.This is an exploratory, single-arm, open-label, phase 1b clinical trial.
- Conditions
- Mesothelioma, Malignant, PD-L1 Negative, Advanced Cancer, Progressive Disease
- Trial name
- MESOVAX (NCT03546426)
- Testing
- Pembrolizumab, Autologous dendritic cells, Interleukin-2
- Where
- Italy
- Volunteers
- 18 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Recurrent Glioblastoma
Neoadjuvant PD-1 Antibody Alone or Combined With DC Vaccines for Recurrent Glioblastoma
Glioblastoma multiforme (GBM) are the most prevalent malignant tumor in central nervous system. At recurrence, no clear standard-of-care therapy is agreed for recurrent GBM (rGBM) and median overall survival is estimated to…
- Trial name
- NCT04888611
- Testing
- Camrelizumab plus GSC-DCV
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Huashan Hospital
Metastatic Pancreatic Cancer
QUILT-3.088: NANT Pancreatic Cancer Vaccine
QUILT-3.088 NANT Pancreatic Cancer Vaccine: Phase II Randomized Trial of the NANT Pancreatic Cancer Vaccine vs. Standard-of-Care as First- Line Treatment for Patients with Metastatic Pancreatic Cancer.
- Trial name
- NCT03563144
- Testing
- Gemcitabine, Nab-paclitaxel, Aldoxorubicin HCl
- Where
- United States
- Sponsor
- ImmunityBio, Inc.